Comparing the Effects of Smoked and Oral Marijuana in Individuals With HIV/AIDS
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00079560 |
Recruitment Status :
Completed
First Posted : March 10, 2004
Last Update Posted : January 11, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infections | Drug: dronabinol | Phase 1 Phase 2 |
Expanded Access : National Institute on Drug Abuse (NIDA) has indicated that access to an investigational treatment associated with this study is available outside the clinical trial.
Little is known about the efficacy and tolerability of oral THC versus smoked MJ in a clinically relevant population. Additionally, it is not clear how THC's effects vary as a function of the duration of treatment or the patient's current patterns of smoked MJ use. This study directly compares 3 doses of smoked marijuana and 3 doses of Marinol across a range of behavioral measures in HIV infected marijuana smokers.
Outcome measures will include analysis of food intake, body composition, mood, physical symptoms (e.g., nausea, stomach pain), psychomotor task performance, and sleep.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 30 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | THC and Marijuana--Effects in Individuals With HIV/AIDS |
Study Start Date : | December 2001 |
Actual Primary Completion Date : | August 2004 |
Actual Study Completion Date : | August 2005 |

- Drug: dronabinol
dronabinol to prevent development of marijuana withdrawal
- daily caloric intake [ Time Frame: daily measure of colories ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years to 50 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
- HIV infected
- Smoke marijuana
- Taking HIV medications
Exclusion criteria
- Naive marijuana smokers
- People with history of respiratory/pulmonary disease

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00079560
United States, New York | |
New York State Psychiatric Institute | |
New York, New York, United States, 10032 |
Principal Investigator: | Margaret Haney, PhD | New York State Psychiatric Institute |
Responsible Party: | Jag H. Khalsa, Ph.D., National Institute on Drug Abuse, NIH |
ClinicalTrials.gov Identifier: | NCT00079560 |
Other Study ID Numbers: |
1R01DA012698-01A1 ( U.S. NIH Grant/Contract ) |
First Posted: | March 10, 2004 Key Record Dates |
Last Update Posted: | January 11, 2017 |
Last Verified: | October 2008 |
HIV Marijuana Marinol |
Oral THC Appetite Complementary Therapies |
Marijuana Abuse Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Dronabinol Hallucinogens Physiological Effects of Drugs Psychotropic Drugs Analgesics, Non-Narcotic |
Analgesics Sensory System Agents Peripheral Nervous System Agents Cannabinoid Receptor Agonists Cannabinoid Receptor Modulators Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Hormones Hormones, Hormone Substitutes, and Hormone Antagonists |